American Association for Cancer Research
10780432ccr200776-sup-238324_2_supp_6498122_qf0kt5.pdf (193.99 kB)

Figure S2 from Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929)

Download (193.99 kB)
journal contribution
posted on 2023-03-31, 22:00 authored by Diane M. Da Silva, Danielle M. Enserro, Jyoti S. Mayadev, Joseph G. Skeate, Koji Matsuo, Huyen Q. Pham, Heather A. Lankes, Katherine M. Moxley, Sharad A. Ghamande, Yvonne G. Lin, Russell J. Schilder, Michael J. Birrer, W. Martin Kast

Figure S2 shows the association of T cell subsets and T cell activation status to ipilimumab dose level received.




NRG Oncology Operations Center

NRG Oncology Statistics and Data Management Center

University of Southern California Norris Comprehensive Cancer Center



A phase I clinical trial (GOG-9929) examined the safety and efficacy of adjuvant immune-modulation therapy with the checkpoint inhibitor ipilimumab [anti–CTL antigen-4 (anti–CTLA-4)] following chemoradiation therapy (CRT) for newly diagnosed node-positive human papillomavirus (HPV)-related cervical cancer. To better understand the mechanism of action and to identify predictive biomarkers, immunologic and viral correlates were assessed before, during, and after treatment. Twenty-one patients who received CRT and ≥2 doses of ipilimumab and 5 patients who received CRT only were evaluable for translational endpoints. Circulating T-cell subsets were evaluated by multiparameter flow cytometry. Cytokines were evaluated by multiplex ELISA. HPV-specific T cells were evaluated in a subset of patients by IFNγ ELISpot. Expression of the activation markers ICOS and PD-1 significantly increased on T-cell subsets following CRT and were sustained or increased following ipilimumab treatment. Combined CRT/ipilimumab treatment resulted in a significant expansion of both central and effector memory T-cell populations. Genotype-specific E6/E7-specific T-cell responses increased post-CRT in 1 of 8 HPV16+ patients and in 2 of 3 HPV18+ patients. Elevation in levels of tumor-promoting circulating cytokines (TNFα, IL6, IL8) post-CRT was significantly associated with worse progression-free survival. Our data indicate that CRT alone and combined with ipilimumab immunotherapy show immune-modulating activity in women with locally advanced cervical cancer and may be a promising therapeutic option for the enhancement of antitumor immune cell function after primary CRT for this population at high risk for recurrence and metastasis. Several key immune biomarkers were identified that were associated with clinical response.